Healthy Volunteers
Conditions
Brief summary
Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.
Detailed description
The purpose of this trial is to evaluate the safety and tolerability of SP-104 relative to naltrexone immediate release capsules in healthy adults. The study is designed to test the hypothesis that the formulation of SP-104 will mitigate against adverse events associated with naltrexone.
Interventions
DRUGSP-104
oral capsule once daily
DRUGNaltrexone immediate release oral capsules
oral capsule once daily
Sponsors
Scilex Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able and willing to read, write, and understand the English language and provide English language written informed consent (IC) prior to beginning any study procedures. 2. Male or female age 18 to 70 years (inclusive) at screening. 3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiogram (ECG), as deemed by the Investigator. 4. Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in. 5. If female, heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of contraception is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission. 6. If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose. 7. Able to swallow capsules. 8. Agrees to comply with all study requirements throughout the entire study period.
Exclusion criteria
1. A body mass index (BMI) \<18 kg/m2 or \>30 kg/m2 (without rounding). 2. Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication. 3. Currently using or have recently used opioids 4. Use of any other investigational drug within 30 days prior to administration of the study medication. 5. History of allergic or adverse response to naltrexone. 6. History of drug or alcohol abuse (\>80 g/day). 7. History of sleep apnea or restless leg syndrome. 8. Serology positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies. 9. Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )). 10. Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements. 11. Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness). 12. Have cancer within the past 5 years (treated or untreated). 13. Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding. 14. Are an employee, family member, sponsor, or student of the Investigator or of the clinical site. 15. Are unable to understand or adhere to the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment emergent adverse events | 1 week |
Countries
New Zealand
Outcome results
None listed